ResearcherWashington University in St. LouisNo recent work listed

Katharine E. Caldwell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4330-9521; OpenAlex author ID A5089790860. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers

Papers 4

Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998 ↗
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible? Co-author DOI 10.1158/1940-6207.capr-20-0426 ↗
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Response Co-author DOI 10.1158/1940-6207.capr-21-0257 ↗
Pancreatic Adenocarcinoma in New Mexico Native Americans: Disparities in Treatment and Survival. Co-author DOI 10.1353/hpu.2019.0045 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chet W. Hammill · 2 shared papers, 2021 · strength 0.50
- Paper Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Response DOI 10.1158/1940-6207.capr-21-0257 ↗
- Paper Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible? DOI 10.1158/1940-6207.capr-20-0426 ↗
Graham D. Hogg · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
William G. Hawkins · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
Chong Zuo · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
Hui Chin Peng · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
C. Alston James · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
Ryan C Fields · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
William E. Gillanders · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
David G DeNardo · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998 ↗
Katherine Teresa Morris · 1 shared paper, 2019 · strength 0.09
- Paper Pancreatic Adenocarcinoma in New Mexico Native Americans: Disparities in Treatment and Survival. DOI 10.1353/hpu.2019.0045 ↗
Alissa A. Greenbaum · 1 shared paper, 2019 · strength 0.09
- Paper Pancreatic Adenocarcinoma in New Mexico Native Americans: Disparities in Treatment and Survival. DOI 10.1353/hpu.2019.0045 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.